In the examples with poor performance, the menu may be confused with the other graphical elements.
The inflammatory phase is characterized by the production of pro-inflammatory mediators and immune cell activation [25 29], and sepsis prognosis is linked to the magnitude and duration of this inflammatory response, high circulating cytokine levels being, for example, associated with poor outcome [30 32].
For example, patients with poor health status are more likely to suffer postoperative morbidity and mortality.
For example, ICUs with poor teamwork climate scores had significantly more respondent comments regarding the need to improve communication, relative to ICUs with high teamwork climate scores.
Networks should explore ways to breakdown barriers between themselves, and work on strategies to strengthen groups perceived as "unpopular" (for example, those with poor management).
For example, individuals with poor phonological representations due to severe long-term hearing impairment may be more unsure than their peers with normal hearing whether "pint" rhymes with "lint" or whether "blue" rhymes with "through".
Deaths during follow up may also relate to the initial brain injury, for example, patients with poor cognitive function after OHCA-VF/VT will be susceptible to dying from pneumonia or other infections during follow up.
For example, people with poor physical health are likely to report greater CVD health needs [ 9], the progression of CVD symptoms is likely to be associated with poor physical health [ 10] and this in consequence is likely to lead to higher hospital admissions and mortality [ 11].
For example, tumours with poor vascularity may escape immunosurveillance to a greater degree than more vascular tumours and it is possible that the relatively poor response rates of pancreas cancers to conventional chemotherapy may also be associated with their avascular nature.
Bacterial antibiotic resistance naturally evolves in such heterogeneous environments, as low-drug habitats unavoidably exist, for example, patients with poor medication adherence in a human population, or organs and tissues of lower drug penetration within the body of a patient (Elliott et al. 1995; Mouton et al. 2008; Fantin et al. 2009).
